ライフサイエンスコーパス: interferon-alpha

1 ion is increased in human cells treated with interferon alpha.

2 on, a defect that was completely reversed by interferon-alpha.

3 en in patients treated with interleukin-2 or interferon-alpha.

4 n a model using the prototypic SLE cytokine, interferon-alpha.

5 ctably translated and induced high levels of interferon-alpha.

6 so ruled out involvement of BAFF, IL-12, and interferon-alpha.

7 s but did not increase in those treated with interferon-alpha (0.58%).

8 MDM2, both alone and combined with pegylated interferon alpha 2a (Peg-IFNalpha 2a), significantly dec

9 f the NLEM decided to include both pegylated interferon alpha 2a and alpha 2b into the NLEM for treat

10 mparing between the combination of pegylated interferon alpha 2a or alpha 2b and ribavirin with a usu

11 , this research determined whether pegylated interferon alpha 2a or alpha 2b plus ribavirin is more c

12 HCV treatment with pegylated interferon alpha 2a or alpha 2b plus ribavirin was domin

13 Pegylated interferon alpha 2a, alpha 2b and ribavirin have been in

14 ort the three-dimensional structure of human interferon alpha-2A (IFN-alpha2A) bound to the Fab fragm

15 of subtenon injections of natural leukocyte interferon alpha-2a (IFNalpha) on best corrected visual

16 Pegylated interferon alpha-2a (PEG-IFN-alpha-2a) has previously be

17 ith vaniprevir in combination with pegylated interferon alpha-2a (Peg-IFN-alpha-2a) plus ribavirin (R

18 Children treated with pegylated interferon alpha-2a (Peg-IFN-alpha2a) +/- ribavirin in t

19 ducted a short-course (4 weeks) of pegylated interferon alpha-2a (Peg-IFN-alpha2a) plus ribavirin (RB

20 ce-daily (BID) in combination with pegylated interferon alpha-2a (Peg-IFNalpha-2a)/ribavirin (RBV).

21 All patients received pegylated interferon alpha-2a (Peg-IFNalpha-2a; 40 kD)/ribavirin (

22 ties of TG4040 in combination with pegylated interferon alpha-2a and ribavirin (PEG-IFNalpha/RBV) in

23 e safety and efficacy of simeprevir with peg-interferon alpha-2a and ribavirin (PR) in a randomized,

24 LCH and ECD improved in response to interferon alpha-2a treatment in only 50% of patients (8

25 factor (EGF) as a cell targeting element and interferon-alpha-2a (IFNalpha-2a) to initiate signal tra

26 After 4 weeks of pegylated interferon-alpha-2a/ribavirin (PEGIFN/RBV) lead-in, pati

27 800 mg/d) plus amantadine (200 mg/d), or PEG interferon alpha 2b (1.0 microg/kg per week) plus ribavi

28 tive patients were randomized to receive PEG interferon alpha 2b (1.0 microg/kg per week), ribavirin

29 ferent antiviral therapy regimens (pegylated interferon alpha 2b and ribavirin different dosages, and

30 are the cost associated with surgical versus interferon-alpha 2b (IFNalpha2b) treatment for ocular su

31 consecutively with topical MMC (0.4 mg/mL), interferon alpha-2b (1 million units/mL), or both for OS

32 f Escherichia coli-derived recombinant human interferon alpha-2b (rhIFN alpha-2b), generated by postt

33 Topical MMC and interferon alpha-2b are an effective treatment method fo

34 ficacy and safety of pretransplant pegylated interferon alpha-2b plus ribavirin (Peg-IFN-alpha2b/RBV)

35 PEG interferon alpha-2b treatment was associated with decrea

36 ed and constant plasma levels of leuprolide, interferon alpha-2b, letrozole, Y-27632, octreotide, and

37 8 weeks of treatment with bevacizumab or PEG interferon alpha-2b.

38 ither bevacizumab (10 mg/kg every 2 wk) with interferon-alpha (3-9 million IU 3 times/wk) (n = 11) or

39 Finally, treatment of thyroid cells with interferon alpha, a known trigger of AITD, increased TG

40 depression in the context of treatment with interferon-alpha, a widely used model to mimic depressio

41 ll eight cases assayed showed elevated serum interferon alpha activity, and gene expression profiling

42 Serum interferon-alpha activity at baseline was significantly

43 nd multiple myeloma) and 9 treatment agents (interferon-alpha, alemtuzumab, bendamustine, bortezomib,

44 by proinflammatory cytokines, which include interferon alpha and gamma and interleukin 2, 2R, 6, 7,

45 Interferon alpha and nucleos(t)ide analogues are 2 class

46 te HCV treated with 24-48 weeks of pegylated interferon alpha and ribavirin, 15 failed to achieve a s

47 ients under various treatment protocols with interferon alpha and/or nucleoside or nucleotide analogs

48 ular endothelial cells confers an ability of interferon-alpha and a soluble IL-6 receptor/IL-6 (sIL-6

49 f type 1 cytokines and chemokines, including interferon-alpha and CXCL10.

50 phalitis virus NS1s in the blood of infected interferon-alpha and gamma receptor-deficient mice (AG6)

51 g CCR5(+) monocytes/macrophages and enhanced interferon-alpha and interferon-gamma production 2 days

52 Consequently, antiviral interferon-alpha and interferon-gamma production, as wel

53 Importantly, SOCS1 coexpression inhibited interferon-alpha and interferon-gamma signaling and prot

54 Interferon-alpha and interferon-lambda production by per

55 ere capable of secreting effector cytokines, interferon-alpha and interleukin-12, respectively, in re

56 d induced the distinct stimulatory cytokines interferon-alpha and interleukin-12, respectively.

57 GS-9620 administration induced production of interferon-alpha and other cytokines and chemokines, and

58 Response to pegylated interferon-alpha and ribavirin (IFN-alpha/RBV) treatment

59 laprevir (TVR) in combination with pegylated interferon-alpha and ribavirin (P/R) for the treatment o

60 eavy alcohol use on treatment with pegylated interferon-alpha and ribavirin (P/R) in an insured house

61 HCV infection in combination with pegylated interferon-alpha and ribavirin in Japan, Canada, and USA

62 roven difficult and the regimen of pegylated interferon-alpha and ribavirin is only effective for hal

63 Although combination therapy of interferon-alpha and ribavirin is reasonably successful

64 levels at baseline of therapy with pegylated interferon-alpha and ribavirin or before biopsy were cor

65 b infection and a null response to pegylated interferon-alpha and ribavirin who developed decompensat

66 pe 1 (TVR, 1125 mg every 12 hours, pegylated interferon-alpha and ribavirin).

67 erapy relies upon a combination of pegylated interferon-alpha and ribavirin, a poorly tolerated regim

68 s with the standard combination of pegylated interferon-alpha and ribavirin.

69 hibitors, used in combination with pegylated interferon-alpha and ribavirin; however, this is just th

70 meth inhibited the expression of endogenous interferon-alpha and signal transducer and activator of

71 e response involving the induction of type I interferons (alpha and beta interferons [IFN-alpha and -

72 Feedback mechanisms between interferons alpha and lambda (IFNs) may be affected by s

73 etroviral therapy, 11 received consolidation interferon-alpha, and 6 received consolidation high-dose

74 taglandin E(2), tumor necrosis factor-alpha, interferon-alpha, and albumin were examined.

75 nown ligands (C3d, Epstein-Barr virus gp350, interferon-alpha, and CD23).

76 ron-beta, 2',5'-oligoadenylate synthetase 1, interferon-alpha, and interferon-alpha-inducible protein

77 an be constitutively expressed or induced by interferon-alpha, and it consists of protein-based tethe

78 rmore, we show that HCV clearance induced by interferon-alpha based antiviral normalized the ER-stres

79 The long-term consequences of unsuccessful interferon-alpha based hepatitis C treatment on liver di

80 d findings suggest that patients who receive interferon-alpha based therapies but fail to clear the h

81 either treatment naive to or relapsed after interferon-alpha based therapy.

82 erwent liver biopsy during consideration for interferon-alpha based treatment between 1992 and 2007.

83 Current interferon alpha-based treatment of hepatitis C virus (H

84 by HIV/HCV coinfected individuals receiving interferon-alpha-based current standard of care.

85 sis, hepatic steatosis, and poor response to interferon-alpha-based therapy.

86 Stat1(-/-) mice lack a response to interferon alpha, beta, and gamma, allowing for replicat

87 Type I interferon (alpha/beta interferon [IFN-alpha/beta]) and

88 virus (MHV) induced the expression of type I interferon (alpha/beta interferon [IFN-alpha/beta]) in m

89 Type I interferon (alpha/beta interferon [IFN-alpha/beta]) stim

90 ing Ebola virus (EBOV) infection, the type I interferon alpha/beta (IFN-alpha/beta) innate immune res

91 The production of type I interferon alpha/beta (IFN-alpha/beta) is crucial to vir

92 signaling cascade resulting in production of interferon alpha/beta (IFN-alpha/beta), which promotes i

93 cently developed in AG129 mice (deficient in interferon alpha/beta and interferon gamma receptor sign

94 t positive correlation between host SOD1 and interferon alpha/beta messenger RNA (mRNA) levels, as we

95 ation of the IFN response through the type I interferon alpha/beta receptor (IFNAR).

96 Neutralizing antibodies against interferon alpha/beta receptor 2 chain (IFNAR2) and tumo

97 -regulation and lysosomal degradation of the interferon alpha/beta receptor chain 1 (IFNAR1) of the r

98 on and disease progression in CCHFV-infected interferon alpha/beta receptor knockout (IFNAR(-/-)) mic

99 red virus replication and spread in infected interferon alpha/beta receptor knockout mice via biolumi

100 action of IFN-beta with its receptor IFNAR1 (interferon alpha/beta receptor subunit 1) is vital for h

101 macrophages (BMMs) and partially restored in interferon alpha/beta receptor-deficient (IFNAR(-/-)) BM

102 etent animals or in animals deficient in the interferon alpha/beta receptor.

103 DD with increased expression of genes in the interferon alpha/beta signaling pathway.

104 ) triple knockout mice, which produce little interferon alpha/beta, and mice lacking the interferon r

105 ro-treated NSCLC cell lines, we elucidate an interferon alpha/beta-based transcriptional program with

106 cells and considered the main source of the interferon-alpha/beta (IFN-alpha/beta), have been found

107 g Vegfa or Vegfr1 without off-target RNAi or interferon-alpha/beta activation.

108 tor 3 activation to induce the expression of interferon-alpha/beta and antiviral/interferon-stimulate

109 ), interferon regulatory factor 3 (IRF3), or Interferon-alpha/beta receptor (IFNAR) by in vivo immort

110 ng the IFN-alphas and IFN-beta, activate the interferon-alpha/beta receptor (IFNAR) complex.

111 phosphorylation-dependent degradation of the interferon-alpha/beta receptor 1 chain of the type I int

112 and Irf7, is propagated by hepatocytes in an interferon-alpha/beta receptor-dependent manner.

113 Interferon-alpha/beta, NOTCH1 signaling pathways and pot

114 nt studies have revealed the existence of an interferon-alpha/beta-independent, innate antiviral resp

115 ISG15 is an interferon-alpha/beta-induced Ubl, and the E1 and E2 enz

116 major host antiviral response by binding the interferon-alpha/beta-induced, ubiquitin-like ISG15 prot

117 on IL-18 in synergy with IL-12, IL-15 and/or interferon-alpha/beta.

118 NF-kappaB-dependent fashion, independent of interferon-alpha/beta.

119 ed alphaviruses differentially induce type I interferons (alpha/beta interferon [IFN-alpha/beta]) in

120 We investigated the role that type I interferons (alpha/beta interferon [IFN-alpha/beta]) mig

121 tic cells (pDCs) are a main source of type I interferons alpha/beta (IFN-alpha/-beta).

122 lasmacytoid DCs can be stimulated to produce interferon-alpha by Cramp/DNA complexes, and we further

123 ion or treatment with ribavirin or pegylated interferon-alpha can result in viral clearance.

124 rmal and stimulated conditions using chicken interferon-alpha (chIFN-alpha) and the attenuated infect

125 ential need for cytoreductive therapies (eg, interferon-alpha, cladribine) in this setting.

126 -6, whereas pDCs account for lower levels of interferon-alpha compared to healthy subjects.

127 mic iron withdrawal as a marker of immediate interferon-alpha efficacy in HCV patients.

128 Moreover, interferon-alpha exposure, which activates dormant HSCs,

129 to arteries, as well as by reduced arterial interferon-alpha expression.

130 age disease (IIB-IV) and include bexarotene, interferon alpha, extracorporeal photopheresis, histone

131 y of plasmacytoid dendritic cells to produce interferon alpha following stimulation of Toll-like rece

132 s and the subsequent production of unopposed interferon-alpha, following a triggering event in predis

133 Interferon-alpha has been exploited as a therapeutic tar

134 ata, hydroxyurea, somatostatin analogues and interferon-alpha have been modestly successful in patien

135 endritic cells (pDCs) produce high levels of interferon alpha (IFN-alpha) and express the apoptotic l

136 Combined treatment with interferon alpha (IFN-alpha) and ribavirin (RBV) can eff

137 ion has been treated with the combination of interferon alpha (IFN-alpha) and ribavirin (RBV) for ove

138 Interferon alpha (IFN-alpha) and ribavirin can induce a

139 he activation of NFkappaB, the expression of interferon alpha (IFN-alpha) and the induction of interf

140 rential induction of key cytokines including interferon alpha (IFN-alpha) and tumor necrosis factor a

141 Although all 12 subtypes of human interferon alpha (IFN-alpha) bind the same receptor, rec

142 atment and may be associated with the use of interferon alpha (IFN-alpha) but also with the primary p

143 n, the two accepted treatment modalities are interferon alpha (IFN-alpha) given subcutaneously for a

144 Interferon alpha (IFN-alpha) is an approved medication f

145 The mechanisms responsible for interferon alpha (IFN-alpha) production by plasmacytoid

146 nhance the rate and magnitude of HIV-induced interferon alpha (IFN-alpha) production.

147 The effect of immune activation on interferon alpha (IFN-alpha) therapy response is unknown

148 pression is one of the major side effects of interferon alpha (IFN-alpha) treatment, but the molecula

149 Protein concentrations of interferon alpha (IFN-alpha), IFN-lambda, and IFN-gamma

150 dendritic cells (pDCs), a primary source of interferon alpha (IFN-alpha), provide a first line of in

151 This is not the case for pegylated interferon alpha (IFN-alpha)-induced neutropenia.

152 The interferon alpha (IFN-alpha)-inducible restriction facto

153 tu PRRSV replication-competent expression of interferon alpha (IFN-alpha).

154 in growth are noted in children treated with interferon alpha (IFN-alpha).

155 s from healthy donors after stimulation with interferon-alpha (IFN-alpha) and anti-immunoglobulin (Ig

156 We report here that although the cytokines interferon-alpha (IFN-alpha) and IFN-beta prevented the

157 proved treatment, a combination of pegylated interferon-alpha (IFN-alpha) and ribavirin, is frequentl

158 Interferon-alpha (IFN-alpha) exhibits its antiviral acti

159 Interferon-alpha (IFN-alpha) has direct inhibitory effec

160 e efficacy and safety of corticosteroids and interferon-alpha (IFN-alpha) in adults with such conditi

161 DCs derived from women produce markedly more interferon-alpha (IFN-alpha) in response to HIV-1-encode

162 Interferon-alpha (IFN-alpha) is a key mediator of antivi

163 ifferent viruses and can act in synergy with interferon-alpha (IFN-alpha) on hepatitis C virus (HCV)

164 whether the elevated levels of HIV-1-induced interferon-alpha (IFN-alpha) production observed in fema

165 kappaB; however, thymocytes deficient in the interferon-alpha (IFN-alpha) receptor IFN-alphaR showed

166 equires interferon-gamma (IFN-gamma) but not interferon-alpha (IFN-alpha) signalling.

167 The ability of interferon-alpha (IFN-alpha) to augment cytidine deamina

168 develop depression within a short timeframe, interferon-alpha (IFN-alpha) treatment for chronic hepat

169 Currently, around 30% of patients receiving interferon-alpha (IFN-alpha) treatment for HCV experienc

170 h risk for recurrence of malignant melanoma, interferon-alpha (IFN-alpha), a stimulator of innate imm

171 ally euthymic patients during treatment with interferon-alpha (IFN-alpha), assessing serum BDNF and r

172 replication during long-term treatment using interferon-alpha (IFN-alpha), IFN-lambda, and ribavirin

173 Two of its ligands, C3d and interferon-alpha (IFN-alpha), inhibited proliferation of

174 Interferon-alpha (IFN-alpha), interleukin-2 (IL-2), tumo

175 ne, are strong predictors of the response to interferon-alpha (IFN-alpha)-based therapy.

176 ronic hepatitis C virus (HCV) infection with interferon-alpha (IFN-alpha).

177 All current therapies of hepatitis C include interferon-alpha (IFN-alpha).

178 d to the secretion of substantial amounts of interferon-alpha (IFN-alpha).

179 e deduced that AGM HSCs show lower levels of interferon-alpha (IFN-alpha)/Jak-Stat1-associated gene e

180 ulate the expression of antiviral cytokines (interferon alpha [IFN-alpha] and IFN-beta) but induced c

181 ity of intranasal treatment with human alpha interferon (alpha-IFN) to reduce lung and nasal wash tit

182 Both interferon alpha (IFNalpha) and immune complexes are pot

183 Interferon alpha (IFNalpha) has been used to treat pancr

184 Polycythemia vera (PV) treatment with interferon alpha (IFNalpha) is frequently limited by dos

185 Interferon alpha (IFNalpha) is important for antiviral a

186 Interferon alpha (IFNalpha) is widely used for treatment

187 We examined the effects of interferon alpha (IFNalpha) on the expression of human m

188 erapeutic options are available, among which interferon alpha (IFNalpha) presents interesting propert

189 ic cells (pDCs) with excessive production of interferon alpha (IFNalpha) represents one of the hallma

190 t tumor necrosis factor alpha (TNFalpha) and interferon alpha (IFNalpha) stimulate PML expression whi

191 The efficacy of interferon alpha (IFNalpha) therapy for chronic hepatiti

192 to show that HIV infection of the thymus and interferon alpha (IFNalpha) treatment alone result in MH

193 into hepatoma cells and inhibit signaling by interferon alpha (IFNalpha), but have no effect on HCV-R

194 Here, we found that interferon alpha (IFNalpha)-secreting MSCs showed more d

195 have demonstrated that high levels of serum interferon-alpha (IFNalpha) activity are a heritable ris

196 vels, lupus-associated autoantibodies, serum interferon-alpha (IFNalpha) activity, 25-hydroxyvitamin

197 production of inflammatory cytokines such as interferon-alpha (IFNalpha) and tumour necrosis factor (

198 Interferon-alpha (IFNalpha) has been implicated in the p

199 Interferon-alpha (IFNalpha) has been used to treat chron

200 Interferon-alpha (IFNalpha) has potent immunostimulatory

201 Interferon-alpha (IFNalpha) has shown promise in the tre

202 Numerous observations implicate interferon-alpha (IFNalpha) in the pathophysiology of sy

203 Interferon-alpha (IFNalpha) is a heritable risk factor f

204 Interferon-alpha (IFNalpha) is a pleomorphic cytokine pr

205 Interferon-alpha (IFNalpha) is a primary pathogenic fact

206 Interferon-alpha (IFNalpha) is an effective treatment of

207 Interferon-alpha (IFNalpha) is an important component of

208 Increased interferon-alpha (IFNalpha) levels and signatures, which

209 Interferon-alpha (IFNalpha) levels are elevated in many

210 TLR) agonists and proteasome inhibitors, and interferon-alpha (IFNalpha) levels were measured by ELIS

211 ary monocyte-derived cells were treated with interferon-alpha (IFNalpha) or IFNalpha-inducing toll-li

212 rosine phosphatases (PTPs) in the absence of interferon-alpha (IFNalpha) response associated with ins

213 nts with systemic sclerosis (SSc) express an interferon-alpha (IFNalpha) signature.

214 ring antiviral therapy, specific delivery of interferon-alpha (IFNalpha) to infected cells may increa

215 pression of genes suggesting the presence of interferon-alpha (IFNalpha), despite the apparent absenc

216 ps of hematopoiesis as well as the effect of interferon-alpha (IFNalpha), which may target the JAK2(V

217 s unknown, the antiosteoclastogenic cytokine interferon-alpha (IFNalpha), whose transcriptome is pres

218 Like SLE monocytes, interferon-alpha (IFNalpha)-primed control monocytes sti

219 However, the role of interferon alpha in immune activation is a double-edged

220 bodies to NETs, and expressed high levels of interferon-alpha in diseased arteries.

221 associated with a reduced ability to induce interferon-alpha in primary human plasmacytoid dendritic

222 dendritic cells (pDCs) produce markedly less interferon-alpha in response to SIV and other Toll-like

223 Bevacizumab/interferon-alpha induced a mean change in tumor SUV(max)

224 ists identify patients at risk of developing interferon-alpha-induced depression, and monitor those r

225 Interferon-alpha-induced genes were expressed at a highe

226 the (NZB x NZW)F(1) (NZB/NZW) mouse model of interferon-alpha-induced lupus nephritis and treated mic

227 owards, the identification and monitoring of interferon-alpha-induced-depression and the decision-mak

228 Here, we show that interferon alpha-inducible protein 6 (IFI6) is necessary

229 denylate synthetase 1, interferon-alpha, and interferon-alpha-inducible protein 27 messenger RNAs of

230 in-12 and interleukin-18), but was bereft of interferon-alpha inducing properties, confirming its hig

231 mary reporter gene assays were paralleled by interferon-alpha induction activities in whole human blo

232 We define a central role for type I interferons (alpha interferon [IFN-alpha] and IFN-beta)

233 proved that autoantibodies directed against interferon-alpha, interferon-beta, interleukin-1alpha (I

234 Interferon alpha is the only treatment option for hepati

235 Furthermore, HCV treatment with interferon-alpha leads to specific MAIT cell activation

236 kinase 2 (JAK2) inhibitors, or low doses of interferon-alpha led to the generation of greater number

237 numbers correlated positively with IL-10 and interferon alpha levels and fewer CD4(+) and CD8(+) T ce

238 Here, we show that monocytes activated by interferon alpha, lipopolysaccharide or a combination of

239 Interferon alpha-mediated STAT1 phosphorylation was high

240 suggested that these genes were involved in interferon alpha, nuclear factor-kappa B (NFkB), extrace

241 ptor enhancing the antireplication effect of interferon-alpha on hepatitis C virus (HCV).

242 ne of HCV RNA was typically slower than with interferon-alpha or protease inhibitors, and 12 patients

243 Because genes involved in the interferon-alpha pathway may affect antiviral responses,

244 Genetic polymorphisms in the interferon-alpha pathway may affect responses to antivir

245 pe 56 polymorphisms found in 13 genes in the interferon-alpha pathway.

246 activation (patients with HCV-infection and interferon-alpha, patients with major depression, and he

247 ials investigating the efficacy of pegylated interferon alpha (PEG-IFNa) showed HDV RNA negativity ra

248 (MDM2) antagonist (RG7112) and the pegylated interferon alpha (Peg-IFNalpha 2a) to target JAK2V617F h

249 Combination treatment with pegylated-interferon-alpha (PEG IFN-alpha) and ribavirin, the curr

250 Egyptian CHC patients treated with Pegylated interferon-alpha (Peg-IFN) plus ribavirin.

251 d difficult to treat in the era of pegylated interferon-alpha (Peg-IFN-alpha) and ribavirin regimens.

252 Pegylated interferon-alpha (PEG-IFN-alpha) forms an integral part

253 The use of pegylated interferon-alpha (pegIFN-alpha) has replaced unmodified

254 Treatment with pegylated interferon alpha (PegIFNalpha) and ribavirin is still re

255 e studied the antiviral potency of pegylated interferon-alpha (pegIFNalpha) against HEV infections in

256 response (SVR) in CHC patients on pegylated interferon alpha plus ribavirin (pegIFNalpha/ribavirin)

257 The outcome of treatment with pegylated interferon alpha plus ribavirin treatment and sustained

258 be reduced to normal range with the standard interferon alpha plus ribavirin treatment.

259 roxyurea, mainly used in older patients, and interferon alpha, primarily given to younger patients.

260 erentially mobilized by plerixafor with high interferon-alpha producing ability.

261 measurable antiviral activity was related to interferon alpha production.

262 DC-expressed MyD88 promoted interferon-alpha production by plasmacytoid DCs, which w

263 not result in significantly higher levels of interferon-alpha production than the levels in mock-infe

264 cytes had impaired STAT1 phosphorylation and interferon-alpha production to CpG stimulation and a den

265 s R892W carrier responded normally to CpG by interferon-alpha production, carrier B cells showed impa

266 We record increased interferon alpha protein levels using digital ELISA, enh

267 Microbial elements, HIV-1, and interferon alpha - putative drivers of HIV-1 associated

268 this question, we introduced a deficiency of interferon alpha receptor 1 (Ifnar1) into B6.Aec1Aec2 mi

269 P also plays an important inhibitory role in interferon-alpha receptor (IFNAR) signaling in mice.

270 1 transcription factor signaling through the interferon-alpha receptor (Ifnar1), resulting in the ant

271 icient to stabilize a similar complex of the interferon-alpha receptor and TYK2.

272 rix metalloproteinase-2 (MMP-2), MMP-13, and interferon alpha-receptors 1 and 2.

273 Aim of this study was to compare ETR to Interferon alpha (recombinant Interferon) & Ribavirin in

274 f direct acting antivirals (DAAs), pegylated interferon-alpha remains the backbone of HCV therapy.

275 mDC2 and pDC produced interferon-lambda and interferon-alpha, respectively.

276 he haplotype (rs12979860) also affects other interferon-alpha responsive chronic viral illnesses, nam

277 on the surface of primary macrophages in an interferon-alpha-responsive manner, captures murine leuk

278 cells with TKI alone, or in combination with interferon-alpha, results in the preferential survival o

279 ort of 876 naive CHC patients, who completed Interferon alpha & Ribavirin for 24 weeks, was studied f

280 ilable therapy for HCV infection is based on interferon-alpha, ribavirin and the new direct-acting an

281 ponsiveness in treatment-naive and pegylated interferon alpha-ribavirin (P/R)-experienced subjects an

282 HCV treated with telaprevir (TVR)/pegylated-interferon alpha/ribavirin.

283 nd safety of standard-therapy with pegylated-interferon-alpha/ribavirin (Peg-IFN-alpha/RBV (48 weeks)

284 imen, with and without concomitant pegylated interferon-alpha/ribavirin therapy.

285 led us to prospectively evaluate recombinant interferon-alpha (rIFNalpha) in "early" PM patients with

286 rculating mononuclear cells revealed reduced interferon-alpha secretion in response to herpes simplex

287 Conventional cytotoxics and interferon-alpha still have an established role in treat

288 Bevacizumab/interferon-alpha strongly decreases tumor uptake whereas

289 Interferon-alpha therapy may be an effective antiviral t

290 d hepatitis B surface antigen (HBsAg) during interferon-alpha therapy.

291 nistration of inflammatory cytokines such as interferon-alpha to otherwise non-depressed controls inc

292 rongly determines the outcome of natural and interferon-alpha treated hepatitis C virus (HCV) infecti

293 In vivo, interferon alpha treatment increased NK cell number and

294 d directly in the care of patients receiving interferon-alpha treatment and had at least one year exp

295 oreover, the specific activation of pDCs and interferon-alpha treatment promoted plaque growth, assoc

296 gated via this method include interleukin-2, interferon-alpha, ubiquitin, antibodies and several sing

297 w-density lipoprotein, whereas production of interferon-alpha was not affected.

298 Cladribine and interferon alpha were therapeutically the most effective

299 signaling and leading to rapid secretion of interferon-alpha, which was essential for the innate ant

300 survival compared with the regimen combining interferon-alpha with 5-fluorouracil-based chemoradiatio